Quick Search (by title or disease)
  

Go to Advanced Search for more options.

Clinical Trials Help

Contact our Cancer Information Line nurse with your questions about open or upcoming clinical trials, second opinions, or patient referrals.
ccinfo@umn.edu • 612-624-2620 • 1-888-226-2376

Esophageal cancer Clinical Trials

Protocol Number Title
2009NTLS011
Tobacco-related Biomarkers in Head and Neck Squamous Cell Carcinoma; Tobacco-Related Biomarkers for Risk Assessment and Prognosis in the Development and Treatment of Head and Neck Squamous Cell Carcinoma; Tobacco carcinogens as markers of exposure, carcinogenesis and risk in oral cancer.
2009NTLS059
Methodology and Development of Tobacco Related Biomarkers Methodology and Development of Tobacco Related Biomarkers, part of 'Metabolism of Carcinogenic Tobacco-Specific Nitrosamines'
2011NTLS081
Evaluating the Effectiveness of Reduced Nicotine Cigarettes, part of "Evaluating New Nicotine Standards for Cigarettes"
2011NTLS154
Benzo[a]pyrene Metabolism: Phenotyping and Genotyping Study 4: Deuterated Phenanthrene and NNK Cigarettes
2012NTLS018
Smoking, Sex Hormones, and Pregnancy
2012NTLS050
PROJECT 4: CLINICAL TRIAL METHODS FOR ASSESSING A TOBACCO PRODUCT part of "MODELS FOR TOBACCO PRODUCT EVALUATION
2012NTLS074
Sex Differences & Progesterone: Association with Impulsivity and Smoking Cessation; Hormones & Smoking Cessation
2015IS087
A Phase I, First-Time-in-Human Study of MEDI9197, a TLR 7/8 Agonist, Administered Intratumorally in Subjects with a Solid Tumor Cancer
2016IS065
An open label, phase Ib, dose-escalation study evaluating the safety and tolerability of xentuzumab and abemaciclib in patients with locally advanced or metastatic solid tumours and in combination with endocrine therapy in patients with locally advanced or metastatic hormone receptor-positive, HER2-, breast cancer, followed by expansion cohorts
2016IS069
A Phase 1/2, Open-Label, Dose-Escalation/Dose-Expansion, Safety and Tolerability Study of INCB057643 in Subjects with Advanced Malignancies
EAY131-Z1C
EAY131-Z1C: MATCH Treatment Subprotocol Z1C: Phase II Study of Palbociclib (PD-0332991) in Patients with Tumors with CDK4 or CDK6 Amplification and Rb Protein Expression by IHC
EAY131-Z1I
EAY131-Z1I: MATCH Treatment Subprotocol Z1I: Phase II Study of AZD1775 in Patients with Tumors Containing BRCA1 and BRCA2 Mutations

12 trials displayed